### 2.2.1 In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of efavirenz. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 315.675         | https://www.drugbank.ca/                                     | Molecular weight                                |
| pK<sub>a</sub>  | 10.1     | (base)          | [Rabel 1996](#5-References)                                | Acid dissociation constant                      |
| Solubility (pH) | mg/mL    | 0.012 (6.4), 0.06 (FaSSIF) | [Cristofoletti 2013](#5-References)        | Water solubility                               |
| logP            | - | 2.07, 4.6 | [Almond 2005](#5-References), https://www.drugbank.ca/     | Partition coefficient between octanol and water |
| logD            | - | 5.1       | [Janneh 2009](#5-References) | Partition coefficient between octanol and buffer solution |
| fu              | - | 0.006 [0.004 - 0.015] | [Almond 2005](#5-References) | Fraction unbound in plasma                      |
| Emax (CYP3A4) | - | 7.27, 3.15 (average 5.21)<br />19.6 | [Shou 2008](#5-References), [Ke 2016](#5-References), [Fahmi 2016](#5-References) | Maximum induction effect |
| EC50 (CYP3A4) | µmol/l | 12.5, 2.18 (average 7.34)<br />4.59, 3.80 | [Shou 2008](#5-References), <br />[Ke 2016](#5-References), [Fahmi 2016](#5-References) | Concentration at half maximum induction |
| Emax (CYP2B6) | - | 6.20, 10.8 | [Ke 2016](#5-References) | Maximum induction effect |
| EC50 (CYP2B6) | µmol/l | 1.62, 1.20 | [Ke 2016](#5-References), [Fahmi 2016](#5-References) | Concentration at half maximum induction |
| Ki (CYP2B6) | µmol/l | 2.7, 2.96, 0.39, 1.38 | [Xu 2013](#5-References), [Fahmi 2016](#5-References) | Concentration for half-maximal inhibition |
| Ki (CYP3A4) | µmol/l | 40.33 | [Xu 2013](#5-References), [Fahmi 2016](#5-References)        | Concentration for half-maximal inhibition |
| fu (incubation) | - | 0.15 | [Ke 2016](#5-References) |  |


### 2.2.2 Clinical Data

A literature search was performed to collect available clinical data on efavirenz in healthy adults.

#### 2.2.2.1 Model Building

The following studies were used for model building:

| Publication                       | Arm / Treatment / Information used for model building        |
| :-------------------------------- | :----------------------------------------------------------- |
| [Mouly 2002](#5-References)       | Healthy subjects receiving  multiple oral doses of 200 and 400 mg |
| [Ogburn 2013](#5-References)      | Healthy subjects receiving a single oral dose of 600 mg      |
| [Xu 2013](#5-References)          | Healthy subjects with different CYP2B6 genotypes receiving a single oral dose of 600 mg |
| [Dooley 2012](#5-References)      | Healthy subjects with different CYP2B6 genotypes receiving multiple doses of 600 mg |
| [Garg 2013](#5-References)        | Healthy subjects receiving multiple doses of 600 mg          |
| [Huang 2012](#5-References)       | Healthy subjects receiving multiple doses of 600 mg          |
| [Cho 2016](#5-References)         | Healthy subjects receiving single dose of 600 mg (with and without rifampicin) |
| [Derungs 2015](#5-References)     | Healthy subjects receiving single dose of 50 mg (with and without rifampicin) |
| [Damle 2008](#5-References)       | Healthy subjects receiving multiple doses of 600 mg          |
| [Ji 2008](#5-References)          | Healthy subjects receiving multiple doses of 600 mg (with and without carbamazepine) |
| [Kharasch 2012](#5-References)    | Healthy subjects receiving multiple doses of 600 mg (with and without alfentanil) |
| [Liu 2008](#5-References)         | Healthy subjects receiving multiple doses of 600 mg (with and without voriconazole) |
| [Malvestutto 2014](#5-References) | Healthy subjects receiving multiple doses of 600 mg          |
| [Soon 2010](#5-References)        | Healthy subjects receiving multiple doses of 600 mg          |



#### 2.2.2.2 Midazolam interaction studies used to parameterize CYP3A4 interaction

The following studies were used for parameterization of CYP3A4 interaction:

| Publication                       | Arm / Treatment / Information used for model building        |
| :-------------------------------- | :----------------------------------------------------------- |
| [Mikus 2017](#5-References)       | Healthy subjects receiving a single oral dose of  400 mg Efavirenz at t=0h, 4 mg midazolam at t=12h and a single intravenous dose of 2 mg midazolam at t=18h. |
| [Katzenmaier 2010](#5-References) | Healthy subjects receiving multiple oral doses of 400 mg efavirenz QD. On day 14, subjects receive a single oral midazolam dose of 3 mg. |
